News
HCM
18.01
-3.90%
-0.73
Weekly Report: what happened at HCM last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at HCM last week (0708-0712)?
Weekly Report · 07/15 09:26
HUTCHMED: A Strong Buy on Global Expansion and Pipeline Potential
TipRanks · 07/10 09:18
Goldman Sachs Keeps Their Hold Rating on HUTCHMED (HCM)
TipRanks · 07/09 19:35
Weekly Report: what happened at HCM last week (0701-0705)?
Weekly Report · 07/08 09:26
Sector Update: Health Care Stocks Advance Late Afternoon
NASDAQ · 07/05 19:59
Hutchmed gains as Ipsen-partnered lymphoma drug undergoes review in China
Seeking Alpha · 07/05 17:41
Why HUTCHMED Stock Is Moving Higher Friday
HUTCHMED's New Drug Application for Tazemetostat for the treatment of follicular lymphoma was accepted in China with priority review status. The treatment is already approved in Japan for the same types of lymphoma. The company's stock is trading higher on Friday.
Benzinga · 07/05 15:56
HUTCHMED’s Cancer Drug Fast-Tracked in China
TipRanks · 07/05 10:29
CK Hutchison Holdings Ltd: A 'China Discount' Is Not Warranted
CK Hutchison Holdings Ltd: A 'China Discount' Is Not Warranted. The company's limited geographic exposure to Greater China makes a "China discount" unwarranted. CK Hutchison pays attractive dividends and is valued at 6.7 times 2023 earnings.
Seeking Alpha · 07/04 15:09
HUTCHMED Announces NDA Acceptance For Tazemetostat In China - Quick Facts
NASDAQ · 07/04 06:51
HUTCHMED ANNOUNCES NDA ACCEPTANCE IN CHINA FOR TAZEMETOSTAT FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA WITH PRIORITY REVIEW STATUS
Reuters · 07/04 00:00
Weekly Report: what happened at HCM last week (0624-0628)?
Weekly Report · 07/01 09:26
HUTCHMED Breaks Below 200-Day Moving Average - Notable for HCM
NASDAQ · 06/28 17:42
HUTCHMED to Announce 2024 Half-Year Financial Results
HUTCHMED (China) Limited will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024. The interim results will be released at 7:00 a.m. Eastern Daylight Time and 7:30 a. M. Hong Kong Time.
Barchart · 06/26 03:30
Goldman Sachs Keeps Their Hold Rating on HUTCHMED (HCM)
TipRanks · 06/25 14:05
Weekly Report: what happened at HCM last week (0617-0621)?
Weekly Report · 06/24 09:28
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
Barchart · 06/24 04:30
Takeda gets EU approval for Fruzaqla for colorectal cancer
Seeking Alpha · 06/21 20:33
HUTCHMED ANNOUNCES EUROPEAN COMMISSION APPROVAL FOR FRUZAQLA® (FRUQUINTINIB) RECEIVED BY TAKEDA
Reuters · 06/21 20:00
More
Webull provides a variety of real-time HCM stock news. You can receive the latest news about Hutchmed (China) Limited through multiple platforms. This information may help you make smarter investment decisions.
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.